The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 365.00
Bid: 360.00
Ask: 370.00
Change: -2.00 (-0.54%)
Spread: 10.00 (2.778%)
Open: 365.00
High: 365.00
Low: 365.00
Prev. Close: 367.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

6 Oct 2021 07:00

RNS Number : 1277O
MaxCyte, Inc.
06 October 2021
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

US57777K1060

Issuer Name

MAXCYTE, INC.

UK or Non-UK Issuer

Non-UK

2. Reason for Notification

An acquisition or disposal of voting rights; An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

Vitruvian Partners LLP

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Name

City of registered office

Country of registered office

Life Tech S.à r.l.

Luxembourg

Luxembourg

5. Date on which the threshold was crossed or reached

24-Sep-2021

6. Date on which Issuer notified

28-Sep-2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

3.110000

0.000000

3.110000

3122500

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

US57777K1060

3122500

3.110000

Sub Total 8.A

3122500

3.110000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

- The Vitruvian Investment Partnership III is managed by Vitruvian Partners LLP and isd eemed to be the ultimate beneficial owner of Life Tech S.à r.l.- The voting rights attached to shares disclosed herein - 3,122,500, equivalent to 3.11% of issuer's voting rights - are comprised by 2,222,500 LSE (AIM) listed shares (LSE SEDOL: BYVJZ42) and by 900,000 US NASDAQ listed shares (NASDAQ: SEDOL BKMQF66).

12. Date of Completion

28-Sep-2021

13. Place Of Completion

London

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLDKPBBKBDBFKK
Date   Source Headline
21st Nov 20197:00 amRNSVor Biopharma Clinical and Commercial License
14th Nov 20197:00 amRNSPresentation at Jefferies Healthcare Conference
7th Nov 20197:00 amRNSMaxCyte to Present at BIO-Europe 2019
1st Nov 20191:04 pmRNSResult of AGM
24th Oct 20197:00 amRNSMaxCyte Advances Phase I Clinical Trial
23rd Oct 20197:01 amRNSPresentations at Cell & Gene Therapy Congress
8th Oct 20197:00 amRNSNotification of AGM and Audit Declaration
7th Oct 20197:00 amRNSEditas Clinical and Commercial License Agreement
30th Sep 20197:00 amRNSUpdates on CARMA Platform at Upcoming Meetings
18th Sep 20197:00 amRNSResults for the Six Months ended 30 June 2019
9th Sep 20197:00 amRNSPresentation at ICLE 2019
14th Aug 20197:00 amRNSNotice of Results
17th Jul 20197:00 amRNSTrading Update
11th Jul 20197:00 amRNSMaxCyte to Host Capital Markets Day Today
5th Jul 20194:42 pmRNSSecond Price Monitoring Extn
5th Jul 20194:36 pmRNSPrice Monitoring Extension
19th Jun 20197:00 amRNSAnnual Report
12th Jun 20197:00 amRNSAppointment of Joint Corporate Broker
29th May 20197:00 amRNSSave the Date: Capital Markets Day
8th May 20194:41 pmRNSSecond Price Monitoring Extn
8th May 20194:36 pmRNSPrice Monitoring Extension
8th May 20197:00 amRNSPhase I Clinical Trial of MCY-M11 Progressed
1st May 20197:00 amRNSASGCT Presentation on First CARMA Drug Candidate
24th Apr 20197:00 amRNSFinal Results for Year Ended 31 December 2018
8th Apr 20197:00 amRNSLaunch of ExPERTT Instrument Family
26th Mar 20197:00 amRNSNotice of Full Year Results
19th Mar 20195:05 pmRNSDirector Dealings
5th Mar 20197:00 amRNSGrant of Options
1st Mar 20197:00 amRNSClinical & Commercial Agreement with Kite
26th Feb 20195:32 pmRNSResult of Special Meeting and Issue of Equity
5th Feb 20194:32 pmRNSResults of Placing
5th Feb 20197:00 amRNSProposed Placing to raise a minimum of £10 million
15th Jan 20197:00 amRNSTrading Update
19th Dec 20187:00 amRNSChange of Auditor
17th Dec 20186:06 pmRNSDirector Dealings
21st Nov 20187:00 amRNSConsolidation of Trading Lines
20th Nov 20187:00 amRNSBlock Admission Six Monthly Return/TVR
16th Nov 20187:00 amRNSWebinar: non-viral cell engineering
14th Nov 20187:00 amRNSClinical and Commercial License Agreement
12th Nov 20187:00 amRNSMaxCyte Announces Research Agreement with Kite
9th Nov 20187:00 amRNSExpansion of CRISPR Commercial License Agreement
31st Oct 20184:25 pmRNSResult of AGM
10th Oct 20187:00 amRNSDosing Begins in First Clinical Trial of MCY-M11
8th Oct 20187:00 amRNSNotice of AGM
24th Sep 20187:00 amRNSResults for the Half Year ended 30 June 2018
10th Sep 20187:00 amRNSGrant of Options
3rd Sep 20187:00 amRNSNotice of Half Year Results
26th Jul 20185:33 pmRNSDirector/PDMR Shareholding
16th Jul 20187:00 amRNSFDA IND Clearance for First Clinical Programme
16th Jul 20187:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.